Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abnormal, adjourn, adjournment, ADSI, adware, AlphaCentric, ankle, arthritogenic, ascending, attack, Baker, belief, beneficiary, Biden, bowel, box, branch, calcineurin, cast, chromatin, Clobex, collagen, contrast, convene, credential, depigmenting, DermBiont, dexamethasone, downregulate, dysregulated, Elidel, Extortion, factual, faster, fleet, gastrointestinal, hardware, harvesting, helper, hematologic, immunoregulatory, inconclusive, inflationary, inquiry, intraperitoneal, IRA, LifeSci, lipopolysaccharide, meaningfully, mezzanine, mixture, monoclonal, multinational, nonsegmental, offline, online, outpace, paw, penalize, pharmacodynamic, phishing, photography, potency, problematic, pronounced, protein, ransomware, rear, recast, reclassed, redemption, remodeling, rest, retaliatory, rheumatoid, Russia, server, solid, stuffing, sublease, subscription, sunset, talent, Tay, Tewksbury, thickening, thrombocytopenia, Tilly, toxicology, UK, Ukraine, ultraviolet, unissued, untreated, whatsoever, withdrew, wrote
Removed:
abbreviated, adjust, age, ANDA, armed, barrier, BBA, billion, bioequivalence, bioequivalent, boycott, building, certification, certify, Circuit, civilian, consummation, contemplated, convert, damaged, decade, delivered, demonstrating, disagreement, disrupted, diversified, dry, East, emergence, enhance, enrolled, equivalence, establishment, excise, exit, filer, flow, function, fundamental, gap, Gaza, goodwill, half, Hezbollah, instability, internally, investigative, Islamist, itch, lawsuit, leasing, Lebanese, leveraging, Middle, mild, missile, moderate, moiety, monotherapy, neighboring, neurokinin, paragraph, parent, people, placebo, plc, practical, precisely, profitably, progression, project, promoted, proven, prurigo, rationale, receptor, reclassification, regimen, region, reinstatement, remanded, remeasured, responder, retrospectively, scientifically, serlopitant, Shiite, significance, situation, stay, Strip, strive, substituted, summer, tablet, terrorist, text, unaudited, unconstitutional, underwriting, unique, upheld, version, withholding
Filing tables
Filing exhibits
Related press release
VYNE similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-255841) and Form S-8 (Nos. 333-263654, 333-253883, 333-229975, 333-237041, and 333-222758) of VYNE Therapeutics Inc. of our report dated March 17, 2022, except for the effects of the reverse stock split discussed in Note 1 and the effects of discontinued operations discussed in Note 4 to the consolidated financial statements, as to which the date is March 14, 2023, relating to the financial statements, which appears in this Form 10-K.
/S/PricewaterhouseCoopers LLP
Florham Park, New Jersey
March 14, 2023